Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01911936 | A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors | PHASE1 | COMPLETED | 12 | — | — | Sep 1, 2013 | Mar 1, 2015 | Dec 17, 2020 | 2 | Japan |
| Arm | Type | Description |
|---|---|---|
| LJM716 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| LM716 | DRUG | - |
Inclusion Criteria: 1. Patients with the following indications: i) (Dose escalation part only): HER2 overexpressing locally advanced/ metastatic breast cancer or gastric cancer for which no effective treatment option exists: * For breast cancer: documented 3+ by immunohistochemistry, or ampl...